News and Trends 10 Jun 2022 Expansion into Europe for BlueRock Therapeutics BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, has established a new site for cell therapy innovation on Bayer’s campus in Berlin, Germany. The move comes as part of the company’s growth strategy. A multidisciplinary BlueRock team will be set up during 2022 to provide clinical development and operational […] June 10, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Inside Labiotech 10 Jun 2022Beyond Biotech – the new Labiotech podcast Labiotech.eu has just gone global with its coverage, and now we are gearing up for the first Labiotech.eu podcast. According to Spotify, in 2021 there were 1.2 million podcasts launched. So does the world need another one? We’d like to think the answer is yes! We are trying to ensure our new podcast, Beyond Biotech, […] June 10, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jun 2022 Ziphius Vaccines and University of Antwerp to work on RNA-based delivery methods Belgian biopharma firm Ziphius Vaccines is set to collaborate with the University of Antwerp to research and develop a lipid library for optimized delivery systems of self-amplifying RNA-based drugs (saRNA) and therapeutics. Messenger RNA (mRNA) vaccines deliver genetic instructions to cells to create proteins that then train the immune system against a pathogen, such as […] June 9, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jun 2022 Amaroq Therapeutics ‘hits early milestones’ in cancer treatment New Zealand biotech company Amaroq Therapeutics said it is progressing towards clinical trials following a promising initial development phase. The company, a start-up spun out of the University of Otago, is focused on developing a new class of therapeutics that target long non-coding RNAs (lncRNA) in cancer. Sarah Diermeier, chief scientific officer and founder of […] June 9, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jun 2022 New Forbion life sciences fund hits €470M European life sciences venture capital firm Forbion, has announced the first €470M ($500M) close of its Forbion Growth Opportunities Fund II. The fund will focus on investing in late-stage European life sciences companies. The new fund has attracted several new institutional investors, including pension funds PME and PMT, the Ewing Marion Kauffman Foundation and Reggeborgh, […] June 9, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jun 2022 Cocuus raises funds to upscale alt-protein 3D bioprinting technology Spanish start-up Cocuus has raised €2.5M ($2.7M) in its pre-Series A funding round. The funds will be used to scale up its 3D bioprinting process for producing plant or cell-based animal protein food analogs. The company recently completed the Eatable Adventures acceleration program, one of the top three global accelerators for foodtech start-ups. Eatable Adventures […] June 9, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jun 2022 Neuroendocrine cancer under the spotlight as Ariceum Therapeutics launches Ariceum Therapeutics, a private biotech company developing a radiopharmaceutical product for the diagnosis and systemic targeted radiation therapy of certain hard-to-treat cancers, has completed an oversubscribed €25M ($26.7M) Series A financing round. Ariceum was co-founded by EQT Life Sciences (formerly LSP) and HealthCap, which also co-led the financing that was joined by Pureos Bioventures. Ipsen […] June 8, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jun 2022 The top European biotech investments in May 2022 Biotech investments in Europe jumped in May 2022 with a large initial public offering from the US/UK firm PepGen. Meanwhile, oncology companies Tubulis, Domain Therapeutics, and EngImmune Therapeutics topped the private biotech investment rounds. Public stock markets remain in a volatile state for biotech companies, with a lot of uncertainty remaining over widespread inflation. Against […] June 8, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jun 2022 New COVID antibody cocktail developed French biotech contract research organization ProteoGenix, Aseem Healthcare, and life sciences consultancy agency Trident Biopharm Solutions have combined on a new antibody cocktail effective against major variants of SARS-CoV-2. The cocktail of four human neutralizing antibodies (AH-5-COV) was generated by screening the plasma of a COVID-19 survivor using ProteoGenix’s phage display platform. The new treatment […] June 8, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jun 2022 Synklino raises €29.8M to trial cytomegalovirus drug Danish biotech Synklino has completed a Series A fundraising round that netted €29.8M ($31.8M). The company is developing drugs for the treatment of chronic viral infections, and the funding will be used for its drug candidate, SYN002, for the treatment of cytomegalovirus (CMV). This will involve both ex vivo and in vivo Phase 1 clinical […] June 8, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jun 2022 United Therapeutics creates 3D printed lung scaffold United Therapeutics Corporation said it has – in partnership with 3D Systems Corporation – produced the world’s most complex 3D-printed object, a human lung scaffold. The human lung scaffold was demonstrated at the LIFE ITSELF Conference, held recently in San Diego, Cal. Martine Rothblatt, United Therapeutics’ chairperson and CEO, and Chuck Hull, 3D Systems’ co-founder, […] June 8, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jun 2022 Cancer vaccine biotech CimCure raises €5M Dutch biotech company CimCure, which is focusing on the development of vaccine-based cancer immunotherapy, has raised more than €5M ($5.3M) in a financing seed round led by Dutch company Positron Ventures. CimCure, a spin-off of the Amsterdam UMC medical center, is set to use the funds to advance its vaccine up to phase 1-2 clinical […] June 7, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email